BJMO - volume 12, issue 3, february 2018
T. Vandamme MD, PhD, Isabelle Maurissen , W. Lybaert MD, Marc Simoens , P. Abrams , A. Driessen MD, PhD, B. Op de Beeck , Wim Demey MD, T. Rondou , M. Ulenaers MD, G. Vanhoutte , Marc Peeters , Steering Committee , NET-specialists
BJMO - volume 12, issue 3, february 2018
T. Vandamme MD, PhD, W. Lybaert MD, Marc Simoens , Wim Demey MD, T. Rondou , P. Abrams , C. Mattelaer , B. Op de Beeck , O. D’Archambeau , G. Roeyen MD, PhD, Lesley De Backer , Marc Peeters , Steering Committee , NET-specialists
BJMO - volume 12, issue 3, february 2018
T. Vandamme MD, PhD, Matthias Beyens , Guy Van Camp , Gitta Boons , Leo Hofland , Marc Peeters , Ken Op de Beeck
BJMO - volume 11, issue 3, may 2017
W. Lybaert MD, M. Simoens , Wim Demey MD, F. van Fraeyenhove MD, T. Vandamme MD, PhD, L. De Backer , M. Peeters MD, PhD
Barcelona, 8-10 March 2017.
(BELG J MED ONCOL 2017;11(3):129–133)
Read moreBJMO - 2017, issue 3, february 2017
W. Lybaert MD, T. Vandamme MD, PhD, M. Simoens , P. Abrams , Wim Demey MD, T. Rondou , M. Ulenaers MD, G. Vanhoutte , M. Peeters MD, PhD, NET specialists NETwerk Steering Committee
BJMO - 2017, issue 3, february 2017
W. Lybaert MD, T. Vandamme MD, PhD, M. Simoens , I. Dero MD, Wim Demey MD, T. Rondou , A. Cuypers , P. Abrams , C. Mattelaer , A. Driessen MD, PhD, B. Op de Beeck , O. D’Archambeau , G. Roeyen MD, PhD, L. De Backer , M. Peeters MD, PhD, NET specialists NETwerk Steering Committee
BJMO - volume 6, issue 2, april 2012
T. Vandamme MD, PhD, V. Deschoolmeester PhD, P. Pauwels MD, PhD, M. Peeters MD, PhD
Targeted therapy with bevacuzimab, cetuximab and panitumumab has expanded the treatment options in metastatic colorectal cancer. Predictive tumour markers for treatment with targeted therapy that have been suggested are Epithelial Growth Factor Receptor (EGFR) and Vascular Endothelial Growth Factor Receptor (VEGFR) expression, KRAS mutation and BRAF mutation status, loss of PTEN and PIK3CA mutation status. Of these, only KRAS has made it into clinical practice. KRAS mutation is a negative predictor for response to cetuximab EGFR inhibitors. No predictive tumour marker for bevacizumab has been identified. In this review, the current evidence on KRAS, BRAF, PTEN, PIK3CA, EGFR and VEGFR expression as predictive tumour markers for targeted therapy is reviewed. (BELG J MED ONCOL 2012;6:52–57)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
